392 related articles for article (PubMed ID: 32181801)
21. Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement.
Novo M; Ruff MW; Skrabek PJ; Lin Y
Mayo Clin Proc; 2019 Nov; 94(11):2361-2364. PubMed ID: 31685159
[No Abstract] [Full Text] [Related]
22. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L
J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Ghione P; Palomba ML; Patel AR; Bobillo S; Deighton K; Jacobson CA; Nahas M; Hatswell AJ; Jung AS; Kanters S; Snider JT; Neelapu SS; Ribeiro MT; Brookhart MA; Ghesquieres H; Radford J; Gribben JG
Blood; 2022 Aug; 140(8):851-860. PubMed ID: 35679476
[TBL] [Abstract][Full Text] [Related]
24. Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel.
Mian A; Wei W; Hamilton BK; Winter AM; Khouri J; Pohlman B; Gerds AT; Jagadeesh D; Anwer F; Kalaycio M; Dean RM; Sobecks R; Caimi PF; Hill BT; Majhail NS
Bone Marrow Transplant; 2023 May; 58(5):590-593. PubMed ID: 36774431
[No Abstract] [Full Text] [Related]
25. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
[TBL] [Abstract][Full Text] [Related]
26. [New European approvals: Tisagenlecleucel and Axicabtagene ciloleucel CAR-T cells - Follicular lymphoma after at least two and three prior lines of therapy].
Cordeil S; Bachy E
Bull Cancer; 2022 Nov; 109(11):1106-1108. PubMed ID: 36088178
[No Abstract] [Full Text] [Related]
27. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
[TBL] [Abstract][Full Text] [Related]
28. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.
Bouchkouj N; Zimmerman M; Kasamon YL; Wang C; Dai T; Xu Z; Wang X; Theoret M; Purohit-Sheth T; George B
Oncologist; 2022 Jul; 27(7):587-594. PubMed ID: 35403693
[TBL] [Abstract][Full Text] [Related]
29. The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel.
Wudhikarn K; Bansal R; Khurana A; Hathcock MA; Bennani NN; Paludo J; Villasboas JC; Wang Y; Johnston PB; Ansell SM; Lin Y
Blood Cancer J; 2021 Jul; 11(7):124. PubMed ID: 34210955
[No Abstract] [Full Text] [Related]
30. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.
Kittai AS; Bond DA; William B; Saad A; Penza S; Efebera Y; Larkin K; Wall SA; Choe HK; Bhatnagar B; Vasu S; Brammer J; Shindiapina P; Long M; Mims A; O'Donnell L; Bhat SA; Rogers KA; Woyach JA; Byrd JC; Jaglowski SM
Blood Adv; 2020 Oct; 4(19):4648-4652. PubMed ID: 33002129
[No Abstract] [Full Text] [Related]
31. Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.
Ping N; Qu C; Bai L; Kang L; Chen X; Wu Q; Xia F; Yu L; Yao H; Wu D; Jin Z
Leuk Lymphoma; 2019 Nov; 60(11):2814-2816. PubMed ID: 31088197
[No Abstract] [Full Text] [Related]
32. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.
Maloney DG; Kuruvilla J; Liu FF; Kostic A; Kim Y; Bonner A; Zhang Y; Fox CP; Cartron G
J Hematol Oncol; 2021 Sep; 14(1):140. PubMed ID: 34493319
[TBL] [Abstract][Full Text] [Related]
33. New Second-Line Treatment for B-Cell Lymphoma.
Aschenbrenner DS
Am J Nurs; 2022 Aug; 122(8):23. PubMed ID: 35862599
[TBL] [Abstract][Full Text] [Related]
34. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.
Jallouk AP; Gouni S; Westin J; Feng L; Mistry H; Steiner RE; James J; Noorani M; Horowitz S; Puebla-Osorio N; Fayad LE; Iyer SP; Hawkins M; Flowers CR; Ahmed S; Nastoupil LJ; Kebriaei P; Shpall EJ; Neelapu SS; Nieto Y; Strati P
Haematologica; 2023 Apr; 108(4):1163-1167. PubMed ID: 36384251
[No Abstract] [Full Text] [Related]
35. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel.
Hoogland AI; Jayani RV; Collier A; Irizarry-Arroyo N; Rodriguez Y; Jain MD; Booth-Jones M; Hyland KA; James BW; Barata A; Bachmeier CA; Chavez JC; Khimani F; Krivenko GS; Lazaryan A; Liu HD; Nishihori T; Pinilla-Ibarz J; Shah BD; Abidi M; Locke FL; Jim HSL
Cancer Med; 2021 Mar; 10(6):1936-1943. PubMed ID: 33641257
[TBL] [Abstract][Full Text] [Related]
36. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.
Riihijärvi S; Fiskvik I; Taskinen M; Vajavaara H; Tikkala M; Yri O; Karjalainen-Lindsberg ML; Delabie J; Smeland E; Holte H; Leppä S
Haematologica; 2015 Feb; 100(2):238-45. PubMed ID: 25381134
[TBL] [Abstract][Full Text] [Related]
37. Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1.
Vadgama S; Mann J; Bashir Z; Spooner C; Collins GP; Bullement A
Value Health; 2022 Jun; 25(6):1010-1017. PubMed ID: 35667774
[TBL] [Abstract][Full Text] [Related]
38. Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES).
Gonzalez Castro LN; Dietrich J; Forst DA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1917-1918. PubMed ID: 30539279
[No Abstract] [Full Text] [Related]
39. Letter to the Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".
Zhang J; Li J; Ma Q; Yang H; Signorovitch J; Wu E
Biol Blood Marrow Transplant; 2020 Dec; 26(12):e333-e334. PubMed ID: 32950695
[No Abstract] [Full Text] [Related]
40. Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".
Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL
Biol Blood Marrow Transplant; 2020 Dec; 26(12):e335-e336. PubMed ID: 32950694
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
